Announced details
Stargardt disease; France's compassionate-use program
Kubota Vision has entered into a supply and license agreement with KÔL. Kubota Vision is responsible for procuring raw materials, manufacturing the active pharmaceutical ingredient and finished products, and handling regulatory matters, while KÔL is responsible for storage and distribution in France, liaison with ANSM, and certain medical affairs activities.
New manufacturing site (location Not disclosed)
The impact on the Company's results is expected to be immaterial.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Emixustat hydrochloride |
| Counterparty | Laboratoires KÔL |
| Relationship with the Company | Kubota Vision has entered into a supply and license agreement with KÔL. Kubota Vision is responsible for procuring raw materials, manufacturing the active pharmaceutical ingredient and finished products, and handling regulatory matters, while KÔL is responsible for storage and distribution in France, liaison with ANSM, and certain medical affairs activities. |
| Contract Date | Supply and license agreement announced on 2 March 2026 (the contract date is not specified) |
| Launch date | April 2026 (scheduled) |
| Applicable area | Stargardt disease; France's compassionate-use program |
| Location | New manufacturing site (location Not disclosed) |
| Impact on Business Performance | The impact on the Company's results is expected to be immaterial. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish a supply system for France's compassionate-use program.